[go: up one dir, main page]

WO2000017143A1 - Derivatives of phenantrene for medicinal use and a process for their preparation - Google Patents

Derivatives of phenantrene for medicinal use and a process for their preparation Download PDF

Info

Publication number
WO2000017143A1
WO2000017143A1 PCT/IT1999/000299 IT9900299W WO0017143A1 WO 2000017143 A1 WO2000017143 A1 WO 2000017143A1 IT 9900299 W IT9900299 W IT 9900299W WO 0017143 A1 WO0017143 A1 WO 0017143A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
retinoic acid
reaction
foregoing
substitutes
Prior art date
Application number
PCT/IT1999/000299
Other languages
English (en)
French (fr)
Italian (it)
Inventor
Khodor Ammar
Original Assignee
Khodor Ammar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khodor Ammar filed Critical Khodor Ammar
Priority to EP99947841A priority Critical patent/EP1119538B1/de
Priority to AT99947841T priority patent/ATE283834T1/de
Priority to AU61201/99A priority patent/AU6120199A/en
Priority to DE69922398T priority patent/DE69922398T2/de
Publication of WO2000017143A1 publication Critical patent/WO2000017143A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/188—Unsaturated ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
    • C07C35/42—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings derived from the phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
    • C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/643—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C07C49/737—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Definitions

  • the present invention relates to new active compounds derived from retinoic acid and suitable for the preparation of pharmaceutical compositions for medicinal use in general, and for use in dermatology, oncology and the treatment of kidney, liver and nervous system disorders; the invention also extends to pharmaceutical compositions containing such compounds, and to the relative preparation method.
  • retinoic acid and its derivatives which are variously effective in preventing and curing tumors by inhibiting cell proliferation, inducing differentiation and apoptosis, and controlling the expression of oncogenes and genes which suppress the tumor.
  • positive results using retinoic acid have been obtained in particular in the treatment of acute promyelocytic leukemia (APL).
  • retinoic acid and its known derivatives also have serious side effects, one of which being hypervitaminosis A, so that a need is felt for a compound which is equally effective therapeutically as retinoic acid, but has significantly less drastic side effects.
  • an active compound for the preparation of pharmaceutical compositions for medicinal use in general, andl for use in dermatology, oncology, and the treatment of kidney, liver and nervous system disorders characterized by the presence of the group of formula (I):
  • lateral substitutes Ri and R 2 are alkyl groups with a carbon number of 1 to 4; both said aliphatic side rings also possibly comprising one or more further lateral substitutes.
  • the active compound according to the invention comprises the group of formula (II):
  • - Ri and R 2 are alkyl groups with a carbon number of 1 to 4;
  • bonds represented by a continuous line alongside a dash line are double or single bonds.
  • the active compound according to the invention preferably comprises the group of formula (III):
  • - Ri and R are alkyl groups with a carbon number of 1 to 4;
  • Ri and R 2 are methyl groups
  • the present invention also relates to a pharmaceutical composition for medicinal use in general, and for use in dermatology, oncology, and the treatment of kidney, liver and nervous system disorders; characterized by comprising the compound defined above, in combination with pharmaceutically compatible excipients.
  • the present invention also relates to a method of preparing pharmaceutical compositions for medicinal use in general, and for use in dermatology, oncology, and the treatment of kidney, liver and nervous system disorders; characterized by comprising the steps of:
  • reaction is preferably produced by bringing said solution to the boil at a temperature of about 187°C. According to a preferred embodiment, said reaction is interrupted after about 60 minutes, and, according to a possible variation, is interrupted after about 120 minutes.
  • the therapeutic effect of the compounds according to the invention has been found to be substantially similar, if not superior, to that of retinoic acid in the treatment of leukemia, as demonstrated by research of cultured leukemic cell lineages.
  • the compounds according to the invention are nontoxic with regard to the cells, even when administered at relatively high (micromolar) concentrations for several consecutive days.
  • the compounds according to the invention also induce apoptosis in the cell lineages, as shown by the fall in the level of bel-2 protein and by DNA fragmentation detected using various techniques : as is known, apoptosis, or programmed cell death, is an important biological process indispensable for normal cell development and differentiation, for maintaining homeostasis, and for virus or tumorous cell elimination by the host; and the tendency to induce apoptosis is an indication of effective therapeutic action.
  • the effects of the compounds according to the invention in terms of differentiation, reducing proliferation and inducing apoptosis are comparable, if not superior, to those of retinoic acid; which test results make it reasonable to assume such compounds will also be therapeutically effective in the treatment of leukemia and any other cases in which the effectiveness of retinoic acid has already been confirmed.
  • the compounds according to the invention and the pharmaceutical compositions containing such compounds have also proved effective in other therapeutical sectors, in particular, dermatology and in the treatment of kidney, liver and nervous system disorders. More specifically, the compounds according to the invention have proved effective in all the cases in which the previous International Patent Application WO 97/02030 filed by the present Applicant indicated the possible use of glycol esters of retinoic acid.
  • BEST MODE FOR CARRYING OUT THE INVENTION A number of purely non-limiting embodiments of the present invention will now be described by way of example.
  • EXAMPLE 1 Preparation of the active compound In a 2-liter vessel, a solution was prepared containing 2 g of retinoic acid in 300 ml of propylene glycol; the esterification reaction of the retinoic acid was initiated by adding 1 mg of salicylic acid as a catalyst and by bringing the solution to a (boiling) temperature of 187°C; the reaction was continued for an hour at the same temperature, and the resulting solution - referred to as solution n.l - was cooled and added to an equal volume of distilled water.
  • the mixture was extracted in three successive stages using 150, 100 and 100 ml respectively of 1,1,2 trichloro-2,2, 1 trifluoro-ethane in a separating funnel; the organic extract was then washed with 100 ml of a 0.1% aqueous solution of potassium bicarbonate (KHCO 3 ) and with 100 ml of distilled water to eliminate the catalyst.
  • KHCO 3 potassium bicarbonate
  • the solvent was removed in a Rotavapor in a stream of nitrogen (known technique).
  • a second sample was prepared in the same way, but with a two-hour hot reaction between the retinoic acid and propylene glycol; and the resulting solution - referred to as solution n.2 - was purified and analyzed in the same way as solution a l.
  • solution n.2 was found to contain crude formula compounds C ⁇ 7 H 20 O and C ⁇ 8 H 2 O of molecular weight 256 and C 17 H 22 O 2 of molecular weight 258, corresponding to the following formulas:
  • Solution n.2 was found to contain about 70% of isomers of molecular weight 256 and less than 10% of those of molecular weight 258.
  • this particular group - comprising three condensed hexagonal rings of carbon atoms, including an aromatic central ring and two saturated or unsaturated aliphatic rings in the meta position - which determines the therapeutic properties of the compounds, regardless of the nature and quantity of the lateral substitutes.
  • EXAMPLE 2 Therapeutic application Both solution n.1 - mainly containing the formula IN compound (molecular weight 330) - and solution n.2 - mainly containing isomer compounds of molecular weight 256 - prepared as described in Example 1 were used to prepare pharmaceutical compositions for various therapeutic applications.
  • the active compounds according to the invention were used pure in low concentrations or diluted in aqueous gly co-alcohol solutions, possibly in combination with hydroquinone and/or salicylic acid.
  • the compounds according to the invention alsoj gave excellent results in the treatment of kidney ailments, cirrhosis of the liver, and nervous disorders.
  • TXB2 thromboxane B2
  • the compounds according to the invention were also found to have the same effects as retinoic acid in inducing apoptosis in leukemia cells, at least at given differentiation stages :
  • Tests were also conducted to determine the effect of the compounds on cytoplasmic protein CRABP I and II and on nuclear protein RAR and RXR, the role played by which in the action of retinoic acid on cell mechanisms (though not yet fully explained) is by now confirmed.
  • Transactivation tests conducted using known techniques have enabled definition of the receptor to which the compound according to the invention is preferentially bonded : test results have shown preferential bonding of the compounds to RXR class receptors, in particular RXR ⁇ , and
  • the compounds according to the invention therefore behave differently as compared with retinoic acid and its traditional derivatives, which, as is known, mainly bond with RAR receptors, whereas the compounds according to the invention preferentially bond with RXR receptors, to which are almost certainly bonded in particular those retinoids capable of inducing apoptosis in HL60 cells [36], in particular the 9-cis form of retinoic acid (the most effective in treating tumors).
  • the compounds according to the invention appear not to induce CRABP II protein : this may be a sign of greater cell stability of the experimental compounds, the differentiating and apoptotic effects of which on transformed cells are thus prolonged.
  • the activity of the new compounds according to the invention has proved comparable with, and in certain respects superior to, that of retinoic acid.
  • EXAMPLE 4 Toxic activity
  • the compounds according to the invention were administered in various forms and concentrations to laboratory animals to determine toxicity.
  • a single-dose test was conducted using forty 21 -week-old Warren stock chickens divided into four inoculation site groups : oral, subcutaneous, intramuscular, intravenous. Half the animals in each group were given 0.1 ml of product, and the other half 1 ml. Following administration of the product, the animals were kept under observation for 21 days to determine : general and/or local reactions, mortality, food and water consumption, and egg production.
  • a repeat-dose test was conducted in the same way using another forty 21- week-old Warren stock chickens, again divided into four inoculation site groups : oral, subcutaneous, intramuscular, intravenous. Half the animals in each group were given 0.1 ml of product, and the other half 1 ml; the same dose was repeated 15 days later; and, following the second dose, the animals were kept under observation for 21 days to determine the same parameters listed above.
  • the proliferation-inhibiting effect of HHP and butyrate on cell lineage CACO- 2 is 80% as compared with 60% for retinoic acid. Inhibition in cell lineage HT-29 treated with HHP of 50 ⁇ M concentration was 95% by the seventh day. 2. HHP is therefore more active on the cells with a lower degree of differentiation.
  • HHP has the same effect as, but none of the side effects of, butyrate, whereas retinoic acid has a lesser and retarded effect.
  • HHP induces in the cell lineages a 3.5 times increase in the number of domes, indicating greater cell differentiation.
  • HHP increases the quantity of ALP (alkaline phosphatase) and is dose-dependent.
  • ALP alkaline phosphatase
  • HHP only increases differentiation and not apoptosis.
  • HHP was tested on neuroblastoma cells, lineage TS-12; and was found to be more active than retinoic acid in terms of cell differentiation, and to have the same effect as sodium butyrate.
  • HHP was also found to reduce somatotropin with a reduction in PSA and a noticeable reduction in prostatic hypertrophy (37 to 27 in one month); to have a regulating effect on estrogen-progesterone with a reduction in estrogens; and to arrest angiogenesis of tumorous cells without affecting healthy blood vessels.
  • HHP large doses (2 g/day) of HHP were administered with no side effects.
  • the drug may be administered diluted in oil to eliminate the propylene glycol.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PCT/IT1999/000299 1998-09-23 1999-09-23 Derivatives of phenantrene for medicinal use and a process for their preparation WO2000017143A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99947841A EP1119538B1 (de) 1998-09-23 1999-09-23 Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren
AT99947841T ATE283834T1 (de) 1998-09-23 1999-09-23 Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren
AU61201/99A AU6120199A (en) 1998-09-23 1999-09-23 Derivatives of phenantrene for medicinal use and a process for their preparation
DE69922398T DE69922398T2 (de) 1998-09-23 1999-09-23 Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998TO000808A IT1304656B1 (it) 1998-09-23 1998-09-23 Derivati dell'acido retinoico per uso medicinale e relativometodo di preparazione.
ITTO98A000808 1998-09-23

Publications (1)

Publication Number Publication Date
WO2000017143A1 true WO2000017143A1 (en) 2000-03-30

Family

ID=11417061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1999/000299 WO2000017143A1 (en) 1998-09-23 1999-09-23 Derivatives of phenantrene for medicinal use and a process for their preparation

Country Status (6)

Country Link
EP (1) EP1119538B1 (de)
AT (1) ATE283834T1 (de)
AU (1) AU6120199A (de)
DE (1) DE69922398T2 (de)
IT (1) IT1304656B1 (de)
WO (1) WO2000017143A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358384B2 (en) 2003-01-16 2008-04-15 Toray Fine Chemicals Co., Ltd. Processes for the recovery of optically active diacyltartaric acids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002030A1 (en) * 1995-06-30 1997-01-23 Khodor Ammar A cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002030A1 (en) * 1995-06-30 1997-01-23 Khodor Ammar A cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. E. CROSS ET AL: "A Novel Rearrangement of trans-Tetrahydroabietic Acid in Sulphuric Acid", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS., no. 22, 1974, CHEMICAL SOCIETY. LETCHWORTH., GB, pages 930 - 931, XP002127927, ISSN: 0022-4936 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358384B2 (en) 2003-01-16 2008-04-15 Toray Fine Chemicals Co., Ltd. Processes for the recovery of optically active diacyltartaric acids

Also Published As

Publication number Publication date
IT1304656B1 (it) 2001-03-28
DE69922398D1 (de) 2005-01-05
AU6120199A (en) 2000-04-10
ITTO980808A1 (it) 2000-03-23
EP1119538B1 (de) 2004-12-01
DE69922398T2 (de) 2005-12-22
EP1119538A1 (de) 2001-08-01
ATE283834T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
US5917084A (en) Antifungal agents
KR100187881B1 (ko) 데커시놀 안젤레이트를 유효성분으로 하는 항암제
EP1119538B1 (de) Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren
CN117466903A (zh) 吲哚二萜生物碱类化合物及其制备方法和应用
CN107722096B (zh) 一种具有抗肿瘤作用的甾体类天然药物及其制备方法和用途
CN107746421B (zh) 化合物dictyopterisin f及其在制备抗肿瘤药物中的应用
JPS6330416A (ja) 脳循環代謝改善剤
US6166074A (en) Pharmaceutical compositions
CN114702467A (zh) 金凤花芳香化cassane二萜类化合物、提取方法及应用
EP3398596A1 (de) Ingenolverbindungen und verwendung davon in der anti-hiv-latenzbehandlung
CN115448826B (zh) 一种天然冰片代谢物的分离与鉴定
CN118930419B (zh) 一种倍半萜二聚体类化合物及其制备方法与应用
CN105801525A (zh) 一种腺苷钴胺的药物组合物及其医药用途
CN105534971A (zh) 二苯并氧杂环庚三烯类化合物在体外筛选或制备药物中的应用
JPH01294657A (ja) 新規アミド化合物及びその製造法
CN118930420B (zh) 一种倍半萜类化合物及其制备方法与应用
CN110204477B (zh) 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用
KR100516647B1 (ko) 당뇨병 치료제 조성물
JPH08310993A (ja) ジテルペン類
JP2000086529A (ja) Ｉｌ−４産生抑制剤
CN118955449A (zh) 紫丁香中的倍半萜类化合物及其制备方法与应用
CN111675688A (zh) 一种具有缩醛结构的木脂素类化合物、制备方法及应用
JPH05229983A (ja) レトロジヒドロカルコン化合物
CN118286205A (zh) 一种大环内酯类化合物在制备血液肿瘤药物中的应用
CN115381807A (zh) 愈创木酚氯贝丁酸酯的保肝活性应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999947841

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999947841

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999947841

Country of ref document: EP